Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

708
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
708
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

279
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
279
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

302
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
302
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

199
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
199
Obesity01:24

Obesity

1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

257
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
257

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sympathetic Reinnervation is Associated With Antihypertensive Treatment Burden and Interstitial Fibrosis After Kidney Transplantation.

Kidney international reports·2026
Same author

Spatially microdissected profiling of tonsillar germinal centers reveals a KLRG1-enriched immune signature in IgA nephropathy.

Frontiers in immunology·2026
Same author

Quantifying Podocyte Depletion and Loss in IgA Nephropathy: A Dual Tissue and Urine Podometric Approach.

Kidney360·2026
Same author

Estimated Glomerular Filtration Rate Slope and Kidney Outcomes in IgA Nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Podometrics as a translational platform for kidney health and disease: Oshima award address 2025.

Clinical and experimental nephrology·2026
Same author

Living donor kidney transplantation after living donor liver transplantation from the same donor in a patient with autosomal dominant polycystic kidney disease: a case report.

CEN case reports·2026

Related Experiment Video

Updated: Feb 18, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.3K

Glomerulopathy Associated With Moderate Obesity.

Yusuke Okabayashi1, Nobuo Tsuboi1, Takaya Sasaki1

  • 1Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

Kidney International Reports
|November 17, 2017
PubMed
Summary
This summary is machine-generated.

Moderately obese individuals (BMI 25-30) can develop a kidney disease similar to obesity-related glomerulopathy. This condition, characterized by low glomerular density, affects patients with moderate obesity and warrants further investigation.

Keywords:
body mass indexglomerular densityhyperfiltrationobesityrenal biopsy

More Related Videos

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.5K
White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

485

Related Experiment Videos

Last Updated: Feb 18, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.3K
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.5K
White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

485

Area of Science:

  • Nephrology
  • Pathology
  • Endocrinology

Background:

  • Obesity-related glomerulopathy is a known kidney disease in individuals with a body mass index (BMI) of 30 kg/m² or higher.
  • However, moderate obesity (BMI < 30 kg/m²) may also be associated with similar renal pathology.

Purpose of the Study:

  • To investigate the occurrence and characteristics of glomerulopathy in patients with moderate obesity (grade 1 obesity).
  • To compare kidney disease features between patients with grade 1 obesity and those with higher grades of obesity.

Main Methods:

  • Retrospective analysis of 20 patients with grade 1 obesity (25 ≤ BMI < 30 kg/m²) and persistent proteinuria.
  • Comparison with 20 patients with grade 2 or higher obesity (BMI ≥ 30 kg/m²) and 31 healthy kidney transplant donors.

Main Results:

  • Patients with grade 1 obesity exhibited male predominance (85%) and high hypertension incidence (80%), similar to the higher obesity group.
  • Histologic findings in grade 1 obesity included low glomerular density and glomerulomegaly, characteristic of obesity-related glomerulopathy.
  • Glomerular density and volume were comparable between grade 1 and grade 2+ obesity groups, differing significantly from healthy controls.

Conclusions:

  • Glomerulopathy resembling obesity-related glomerulopathy can affect individuals with moderate obesity.
  • Factors such as low glomerular density may contribute to susceptibility to this kidney disease, independent of BMI alone.